U-Neuron Biomedical Inc (6973.TWO)
TWD 40.25
(0.5%)
TWD 40.25
(0.5%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 27.02 Million | 26.78 Million | 28.41 Million |
| Cost of Revenue | 5.46 Million | 5.2 Million | 4.48 Million |
| Gross Profit | 21.56 Million | 21.58 Million | 23.93 Million |
| Operating Expenses | 21.56 Million | 65.25 Million | 38.99 Million |
| Selling, General and Administrative Expenses | 34.57 Million | 18.48 Million | 12.51 Million |
| Research and Development Expenses | 77.31 Million | 46.76 Million | 26.47 Million |
| Other Expenses | - | -1.14 Million | 3.13 Million |
| Cost and Expenses | 117.34 Million | 70.46 Million | 43.48 Million |
| Operating Income | -84.83 Million | -43.06 Million | -11.25 Million |
| Interest Expense | 55 Thousand | 109 Thousand | - |
| Income Tax Expense | - | - | - |
| Earnings before Tax | -84.89 Million | -43.17 Million | -11.25 Million |
| Net Income | -84.89 Million | -43.17 Million | -11.25 Million |
| Earnings Per Share Basic | -3.21 | -2.88 | -0.99 |
| Earnings Per Share Diluted | -3.21 | -2.88 | -0.99 |
| Weighted Average Shares Outstanding | 26.46 Million | 15 Million | 11.37 Million |
| Weighted Average Shares Outstanding (Diluted) | 26.46 Million | 15 Million | 11.37 Million |
| Gross Margin | 0.80 | 0.81 | 0.84 |
| EBIT Margin | -2.88 | -1.36 | -0.34 |
| Profit Margin | -3.14 | -1.61 | -0.40 |
| EBITDA | -77.87 Million | -36.52 Million | -9.61 Million |
| Earnings Before Tax Margin | -3.14 | -1.61 | -0.40 |
| Breakdown | 2024 Q2 | 2023 FY | 2023 Q4 | 2023 Q2 | 2022 FY | 2021 FY |
|---|---|---|---|---|---|---|
| Revenue | 20.8 Million | 27.02 Million | 15.02 Million | 12 Million | 26.78 Million | 28.41 Million |
| Cost of Revenue | 5.6 Million | 5.46 Million | 5.35 Million | 4.22 Million | 5.2 Million | 4.48 Million |
| Gross Profit | 15.19 Million | 21.56 Million | 9.66 Million | 7.77 Million | 21.58 Million | 23.93 Million |
| Operating Expenses | 50.97 Million | 111.88 Million | 42.21 Million | 65.54 Million | 65.25 Million | 38.99 Million |
| Selling, General and Administrative Expenses | 12.79 Million | - | 11.48 Million | 20.08 Million | - | - |
| Research and Development Expenses | 38.17 Million | - | 30.73 Million | 45.45 Million | - | - |
| Other Expenses | - | 121 Thousand | - | - | -1.14 Million | 3.13 Million |
| Cost and Expenses | 56.57 Million | 117.34 Million | 47.57 Million | 69.77 Million | 70.46 Million | 43.48 Million |
| Operating Income | -35.77 Million | -84.83 Million | -32.55 Million | -57.77 Million | -43.06 Million | -11.25 Million |
| Interest Expense | 131 Thousand | 55 Thousand | 27 Thousand | 28 Thousand | 109 Thousand | - |
| Income Tax Expense | 3.56 Million | - | 3.75 Million | 1.72 Million | - | - |
| Earnings before Tax | -32.34 Million | -84.89 Million | -28.82 Million | -56.06 Million | -43.17 Million | -11.25 Million |
| Net Income | -32.34 Million | -84.89 Million | -28.82 Million | -56.06 Million | -43.17 Million | -11.25 Million |
| Earnings Per Share Basic | -1.09 | - | -0.91 | -2.63 | - | - |
| Earnings Per Share Diluted | -1.09 | - | -0.91 | -2.63 | - | - |
| Weighted Average Shares Outstanding | 29.55 Million | 15 Million | 31.5 Million | 21.33 Million | 15 Million | 11.37 Million |
| Weighted Average Shares Outstanding (Diluted) | 29.55 Million | 15 Million | 31.5 Million | 21.33 Million | 15 Million | 11.37 Million |
| Gross Margin | 0.73 | 0.80 | 0.64 | 0.65 | 0.81 | 0.84 |
| EBIT Margin | -1.36 | - | -1.68 | -4.38 | - | - |
| Profit Margin | -1.55 | -3.14 | -1.92 | -4.67 | -1.61 | -0.40 |
| EBITDA | -28.26 Million | - | -25.25 Million | -52.61 Million | - | - |
| Earnings Before Tax Margin | -1.72 | -3.14 | -2.17 | -4.81 | -1.61 | -0.40 |
IVT
256150
6846
035150
EKTR4
EGL